A detailed history of Manufacturers Life Insurance Company, The transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Manufacturers Life Insurance Company, The holds 238,055 shares of RARE stock, worth $10 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
238,055
Previous 247,138 3.68%
Holding current value
$10 Million
Previous $10.2 Million 30.19%
% of portfolio
0.01%
Previous 0.01%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$40.21 - $59.36 $365,227 - $539,166
-9,083 Reduced 3.68%
238,055 $13.2 Million
Q2 2024

Aug 14, 2024

SELL
$37.42 - $51.61 $1.51 Million - $2.08 Million
-40,366 Reduced 14.04%
247,138 $10.2 Million
Q1 2024

May 14, 2024

BUY
$43.02 - $53.69 $652,398 - $814,208
15,165 Added 5.57%
287,504 $13.4 Million
Q4 2023

Feb 13, 2024

BUY
$31.73 - $49.19 $998,923 - $1.55 Million
31,482 Added 13.07%
272,339 $13 Million
Q3 2023

Nov 15, 2023

SELL
$34.92 - $46.66 $72,319 - $96,632
-2,071 Reduced 0.85%
240,857 $8.59 Million
Q2 2023

Aug 11, 2023

BUY
$37.35 - $52.15 $5.93 Million - $8.28 Million
158,708 Added 188.44%
242,928 $11.2 Million
Q1 2023

May 15, 2023

SELL
$36.99 - $48.71 $339,864 - $447,547
-9,188 Reduced 10.91%
75,032 $3.01 Million
Q4 2022

Aug 11, 2023

BUY
$33.72 - $46.33 $302,974 - $416,275
8,985 Added 11.94%
84,220 $3.9 Million
Q4 2022

Feb 13, 2023

BUY
$33.72 - $46.33 $302,974 - $416,275
8,985 Added 11.94%
84,220 $3.9 Million
Q3 2022

Aug 11, 2023

SELL
$39.96 - $66.14 $437,761 - $724,563
-10,955 Reduced 12.71%
75,235 $3.12 Million
Q3 2022

Nov 03, 2022

SELL
$39.96 - $66.14 $437,761 - $724,563
-10,955 Reduced 12.71%
75,235 $3.05 Million
Q2 2022

Aug 11, 2023

BUY
$45.8 - $85.4 $109,736 - $204,618
2,396 Added 2.86%
86,190 $5.14 Million
Q2 2022

Aug 15, 2022

BUY
$45.8 - $85.4 $109,736 - $204,618
2,396 Added 2.86%
86,190 $5.19 Million
Q1 2022

Aug 11, 2023

BUY
$62.2 - $84.4 $544,996 - $739,512
8,762 Added 11.68%
83,794 $6.09 Million
Q1 2022

May 20, 2022

BUY
$62.2 - $84.4 $5.21 Million - $7.07 Million
83,794 New
83,794 $5.98 Million
Q2 2021

Aug 12, 2021

SELL
$92.19 - $115.71 $3.28 Million - $4.12 Million
-35,571 Closed
0 $0
Q1 2021

May 03, 2021

SELL
$106.9 - $167.73 $174,353 - $273,567
-1,631 Reduced 4.38%
35,571 $4.05 Million
Q4 2020

Feb 12, 2021

BUY
$84.4 - $177.39 $343,592 - $722,154
4,071 Added 12.29%
37,202 $5.15 Million
Q3 2020

Nov 09, 2020

SELL
$72.98 - $90.0 $43,350 - $53,460
-594 Reduced 1.76%
33,131 $2.72 Million
Q2 2020

Aug 10, 2020

SELL
$46.91 - $78.22 $45,127 - $75,247
-962 Reduced 2.77%
33,725 $2.48 Million
Q1 2020

May 15, 2020

BUY
$33.8 - $62.9 $60,772 - $113,094
1,798 Added 5.47%
34,687 $1.54 Million
Q4 2019

Feb 14, 2020

SELL
$36.08 - $45.83 $34,745 - $44,134
-963 Reduced 2.84%
32,889 $1.41 Million
Q3 2019

Nov 12, 2019

BUY
$42.5 - $63.11 $4,420 - $6,563
104 Added 0.31%
33,852 $1.44 Million
Q2 2019

Aug 14, 2019

SELL
$54.93 - $74.36 $20,543 - $27,810
-374 Reduced 1.1%
33,748 $2.14 Million
Q1 2019

May 13, 2019

BUY
$39.87 - $69.36 $201,104 - $349,851
5,044 Added 17.35%
34,122 $2.37 Million
Q4 2018

Feb 14, 2019

SELL
$38.89 - $77.3 $52,268 - $103,891
-1,344 Reduced 4.42%
29,078 $1.26 Million
Q3 2018

Nov 14, 2018

SELL
$71.81 - $90.15 $306,556 - $384,850
-4,269 Reduced 12.31%
30,422 $2.32 Million
Q2 2018

Aug 14, 2018

BUY
$48.54 - $85.31 $70,091 - $123,187
1,444 Added 4.34%
34,691 $2.67 Million
Q1 2018

May 15, 2018

BUY
$44.33 - $58.52 $124,478 - $164,324
2,808 Added 9.23%
33,247 $1.7 Million
Q4 2017

Feb 08, 2018

BUY
$43.54 - $57.32 $4,571 - $6,018
105 Added 0.35%
30,439 $1.41 Million
Q3 2017

Nov 14, 2017

BUY
$49.79 - $66.32 $1.51 Million - $2.01 Million
30,334
30,334 $1.62 Million

Others Institutions Holding RARE

About Ultragenyx Pharmaceutical Inc.


  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $2.95B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track This Portfolio

Track Manufacturers Life Insurance Company, The Portfolio

Follow Manufacturers Life Insurance Company, The and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Manufacturers Life Insurance Company, The, based on Form 13F filings with the SEC.

News

Stay updated on Manufacturers Life Insurance Company, The with notifications on news.